Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 5/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.35 |
| ▸ | CCR1 | P32246 | 3/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL976396 | 0.94 | NSD2 (0.34) | IDO1KCNH2CYP2C9NSD2CNR1 | |
| SCHEMBL977233 | 0.91 | CNR1 (0.35) | IDO1KCNH2CYP2C9NSD2CNR1 | |
| SCHEMBL977629 | 0.90 | CCR1 (0.37) | CCR1CNR1OPRM1OPRD1SLC6A9 | |
| SCHEMBL975645 | 0.89 | TRPA1 (0.35) | IDO1KCNH2CCR1NSD2CNR1 | |
| SCHEMBL976727 | 0.89 | CCR1 (0.36) | CCR1CNR1OPRM1OPRD1SCN9A | |
| SCHEMBL975653 | 0.89 | CCR1 (0.36) | CCR1CNR1CNR2OPRM1OPRD1 | |
| SCHEMBL977225 | 0.88 | CCR1 (0.35) | IDO1KCNH2CCR1CYP2C9SCN9A | |
| SCHEMBL977665 | 0.87 | CNR1 (0.35) | IDO1KCNH2CYP2C9CNR1CNR2 | |
| SCHEMBL977666 | 0.87 | CNR1 (0.35) | IDO1KCNH2CYP2C9CNR1CNR2 | |
| SCHEMBL975115 | 0.86 | CCR1 (0.40) | CCR1CNR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2234966-B1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | SANOFI SA (FR) | 2013-09-11 | — | — | EP | claimed |
| US-8445478-B2 | Azetidine derivatives, their preparation and their application in therapy | SANOFI (FR) | 2013-05-21 | — | — | US | claimed |
| US-20110009377-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | claimed |
| US-20130237513-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | SANOFI (FR) | 2013-09-12 | — | — | US | disclosed |
| US-8445478-B2 | Azetidine derivatives, their preparation and their application in therapy | SANOFI (FR) | 2013-05-21 | — | — | US | disclosed |
| US-20110009377-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237513-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | QDPR, AZI2, ADRA1B | IDO1 432/4885KCNH2 124/4885CCR1 1721/4885 |
| US-20110009377-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | QDPR, AZI2, ADRA1B | IDO1 432/4885KCNH2 124/4885CCR1 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.